Nifty Pharma Gains 1% as US Grants Zero-Tariff Relief on Indian Speciality Medicines

The Nifty Pharma index rose 1% in Tuesday's trading session, standing out as a resilient pocket of strength in an otherwise weak domestic equity market. The sectoral rally unfolded even as the broader benchmark indices came under intense selling pressure, with the BSE Sensex tumbling as much as 708 points to 72,064 and the Nifty 50 falling 210 points to an intraday low of 22,570.

Investor sentiment across pharmaceutical counters improved sharply after the US Department of Commerce published a notification placing India on a list of 20 partner jurisdictions eligible for zero per cent ad valorem tariffs on qualifying speciality medicines and ingredients.

Scope of the US Tariff Exemption

The targeted zero-duty status comes under the implementation of Section 232 rules stemming from an April presidential proclamation designed to shift pharmaceutical manufacturing towards the United States. While Washington is enforcing a 100% tariff on specified patented pharmaceutical imports and associated ingredients, qualifying products from eligible jurisdictions will face no import levy.

The Commerce Department's Bureau of Industry and Security clarified that the exemption applies to select medical segments meeting urgent health needs or trade framework criteria:

• Orphan drugs used in treating rare diseases
• Fertility and infertility treatments
• Advanced cell therapies and gene therapies
• Antibody-drug conjugates (ADCs)
• Nuclear medicines and plasma-derived therapies
• Animal-health products and veterinary pharmaceuticals
• Associated active ingredients and key starting materials

Significance for Indian Drugmakers

The clarification provides essential regulatory certainty for Indian pharmaceutical manufacturers. The US Commerce Department previously confirmed that generic pharmaceutical products and their associated ingredients are not subject to the Section 232 tariffs. Because generic formulations form the backbone of Indian pharmaceutical shipments to the US, the core trade corridor remains protected.

However, Indian pharmaceutical leaders have been aggressively deploying capital into complex generics, biologics, and rare-disease therapies to expand value-added margins in developed markets. The confirmation that India is among the 20 exempted jurisdictions alongside partners like the European Union, the United Kingdom, Japan, and South Korea removes the threat of steep border taxes on these fast-growing speciality pipelines.

The relief provided domestic investors with a defensive anchor during the trading session, allowing pharma stocks to decouple from the broader market downturn triggered by surging crude oil prices and elevated US bond yields.

Tags: Nifty Pharma US Department of Commerce Indian Pharmaceutical Sector BSE Sensex Nifty 50